» Articles » PMID: 36839767

Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2023 Feb 25
PMID 36839767
Authors
Affiliations
Soon will be listed here.
Abstract

Nicardipine hydrochloride is an anti-hypertensive drug that is used off-label to treat hypertension in children. A previous oral formulation of nicardipine hydrochloride was developed using a commercial vehicle as an excipient. However, ready-to-use vehicles are prone to supply shortages, and their composition may undergo substantial modifications. The aim of this study was to propose a new oral formulation of nicardipine hydrochloride 2 mg/mL using simple excipients. The formulation included hydroxypropylmethylcellulose, simple syrup, polysorbate 80, sodium saccharin, citrate buffer, strawberry flavor and 0.2% potassium sorbate. The uniformity of content was maintained before and after agitation. Nicardipine hydrochloride concentration assessed by HPLC-MS/MS remained above 90% for 365 days before opening and for 28 days after opening. pH and osmolality were maintained throughout the study, and no microbial contamination was observed. The uniformity of mass of the delivered doses was evaluated using four different devices. A new oral formulation of nicardipine hydrochloride 2 mg/mL was developed using simple and safe excipients. Pharmacological and clinical parameters remain to be assessed and compared with those of the previous formulation.

Citing Articles

Development of Personalised Immediate-Release Gel-Based Formulations Using Semi-Solid Extrusion.

Aina M, Baillon F, Sescousse R, Sanchez-Ballester N, Begu S, Soulairol I Gels. 2024; 10(10).

PMID: 39451318 PMC: 11507880. DOI: 10.3390/gels10100665.


Devices for securing and administering pediatric compounded oral liquids: survey results from French university hospitals.

Cavelier M, Hervouet C, Varin R, Gonde H Eur J Pediatr. 2024; 183(6):2805-2810.

PMID: 38573361 DOI: 10.1007/s00431-024-05547-x.

References
1.
Kriegel C, Festag M, Kishore R, Roethlisberger D, Schmitt G . Pediatric Safety of Polysorbates in Drug Formulations. Children (Basel). 2019; 7(1). PMC: 7022221. DOI: 10.3390/children7010001. View

2.
Schrier L, Hadjipanayis A, Stiris T, Ross-Russell R, Valiulis A, Turner M . Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr. 2020; 179(5):839-847. DOI: 10.1007/s00431-019-03556-9. View

3.
Salunke S, Clapham D, Agrawal A, Hughes K, Nunn T . Best practices for selection of excipients for paediatrics - Workshop reflection. Eur J Pharm Biopharm. 2021; 160:77-81. DOI: 10.1016/j.ejpb.2020.12.021. View

4.
Fuss D, Gonde H, Lamoureux F, Pereira T, Colnot M, Buchbinder N . Stability study of a compounded oral solution of nicardipine for the treatment of hypertension in children. Eur J Pharm Sci. 2021; 160:105738. DOI: 10.1016/j.ejps.2021.105738. View

5.
Santovena A, Suarez-Gonzalez J, Martin-Rodriguez C, Farina J . Formulation design of oral pediatric Acetazolamide suspension: dose uniformity and physico-chemical stability study. Pharm Dev Technol. 2016; 22(2):191-197. DOI: 10.1080/10837450.2016.1175475. View